In contrast, antibodies that distinguished COVID-hospitalised controls, including aCL IgA and IgG, were associated with hypercoagulability (elevated D-dimer), respiratory and renal disease (increasing creatinine), thereby exhibiting features of the thrombo-inflammatory complications seen in COVID-19 [1,24]. This evidence concerns the gene ACLY and kidney disorder.